Form 4: Korro Bio Director Katharine Knobil Granted Stock Options Valued at $14.87 Per Share

Korro Bio, Inc. (KRRO) has reported that Director Katharine Knobil was granted 6,010 stock options with an exercise price of $14.87 per share, vesting on the earlier of one year from the grant date or the next annual stockholders' meeting.

Summary

• Korro Bio, Inc. (KRRO) Director Katharine Knobil was granted 6,010 stock options on June 11, 2025.
• The exercise price for these stock options is $14.87 per share.
• The options are set to vest in full on the earlier of the one-year anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders.
• Vesting is contingent upon Katharine Knobil's continued service as a non-employee director through the applicable vesting date.
• The stock options have an expiration date of June 10, 2035.
• Following this transaction, Katharine Knobil beneficially owns 6,010 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event for a director, which is a positive for governance and alignment, but it doesn't indicate any significant operational or financial news for the company.

Positives

• The grant of stock options to Director Katharine Knobil aligns her financial interests with those of the company's shareholders, incentivizing long-term performance.
• This is a standard form of compensation for non-employee directors, indicating normal corporate governance practices.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholders' equity, although the number of shares is relatively small.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic outlook, focusing solely on an insider transaction.

Industry Context

This filing is a routine disclosure of an insider transaction, specifically the grant of stock options to a director as part of their compensation. Such grants are common practice across various industries, including biotechnology, to align management and director interests with shareholder value.

Corporate Governance

Related Party Transactions

• The grant of 6,010 stock options to Katharine Knobil, a director of Korro Bio, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential minor future dilution upon option exercise, but also improved alignment of director's interests with shareholder value.
• Director (Katharine Knobil): Receives equity-based compensation, incentivizing long-term commitment and performance.

Next Steps

• The stock options will vest on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Korro Bio, KRRO, SEC Form 4, stock options, director compensation, insider transaction, beneficial ownership, equity compensation, corporate governance